Cytokinetics/$CYTK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytokinetics
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Ticker
$CYTK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
498
ISIN
US23282W6057
Website
Cytokinetics Metrics
BasicAdvanced
$3.6B
-
-$5.30
0.81
-
Price and volume
Market cap
$3.6B
Beta
0.81
52-week high
$61.38
52-week low
$29.31
Average daily volume
2.3M
Financial strength
Current ratio
5.986
Quick ratio
5.887
Long term debt to equity
-329.534
Total debt to equity
-341.746
Interest coverage (TTM)
-6.14%
Management effectiveness
Return on assets (TTM)
-34.12%
Return on equity (TTM)
185.72%
Valuation
Price to revenue (TTM)
184.202
Price to book
-13.64
Price to tangible book (TTM)
-13.64
Price to free cash flow (TTM)
-8.686
Growth
Revenue change (TTM)
412.21%
Earnings per share change (TTM)
-1.93%
3-year revenue growth (CAGR)
-33.39%
3-year earnings per share growth (CAGR)
18.21%
What the Analysts think about Cytokinetics
Analyst ratings (Buy, Hold, Sell) for Cytokinetics stock.
Cytokinetics Financial Performance
Revenues and expenses
Cytokinetics Earnings Performance
Company profitability
Cytokinetics News
AllArticlesVideos
Cytokinetics, Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cytokinetics, Incorporated (CYTK)
Accesswire·9 hours ago
Cytokinetics, Incorporated (CYTK) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Accesswire·1 day ago
Protect Your Investment: Contact Levi & Korsinsky About the Cytokinetics, Incorporated (CYTK) Investigation
Accesswire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytokinetics stock?
Cytokinetics (CYTK) has a market cap of $3.6B as of May 23, 2025.
What is the P/E ratio for Cytokinetics stock?
The price to earnings (P/E) ratio for Cytokinetics (CYTK) stock is 0 as of May 23, 2025.
Does Cytokinetics stock pay dividends?
No, Cytokinetics (CYTK) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Cytokinetics dividend payment date?
Cytokinetics (CYTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytokinetics?
Cytokinetics (CYTK) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.